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2015 年 10 月 5 日，历时 5 年的磋商与谈判，美国同 11 个环太平洋国家在美国
亚特兰大举行的部长会议上达成跨太平洋伙伴关系协定（TPP）。在美国正式宣布退



















































After negotiation and consultation for 5years, Trans-Pacific Partnership Agreement 
eventually was achieved between America and eleven Pacific Rim countries in council of 
ministers hold in Atlanta in October, 2015. However, Donald Trump, the new president 
of America, signed an administration order which announces withdraw from TPP 
formally. After that, the other member states begin to adjust their own coping strategy, 
and China has possibility to be the new leading country. Furthermore, the clauses about 
intellectual property in TPP have indicated that this agreement will challenge and affect 
the world intellectual property regime, so the research and discussion on TPP should be 
in more detailed scale. 
There are three parts in this paper. In the first part, the author will discuss the 
influence path and result of TPP on pharmaceuticals industry. Based on the content of 
TPP about data exclusivity, parallel import, refine the effect on specific industry, and 
provide a theoretical basis for researching different effects of TRIPS-Plus clauses on 
pharmaceuticals industry in developed countries or developing countries. In the second 
part, the countermeasures of Singapore, Jordan, Australia and India to cope some similar 
agreements before TPP will be discussed. There is a great deal of similar multilateral 
agreements or bilateral agreements before TPP. The analysis of the change to domestic 
medicine system and their coping strategy will be an important reference for applicability 
of TPP in Chinese specific conditions. In the third part is the situation faced by China and 
the measures should be taken. With the withdrawal of America, the other member states 
seek help from China to make TPP into force successfully. The author based on the 
discussion about legislation and administration of justice of IPR in China, find the 
answer about whether China join in the TPP and the results. 
There are two creative points in this thesis. Firstly, this paper comprehensive 
analyses the measures of different developing countries to reply the TRIPS-Plus trend. 
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引  言 
1 
 
引    言 
美国总统特朗普于 2017 年 1 月 23 日签署行政命令，宣布正式退出 TPP 协定，
TPP 协定的谈判磋商以及后续成员国的变动情况随即被推上风口浪尖。TPP 协定定
位于目前为止世界最大的自贸协定（FTA），参与国加总经济比重占全球经济总量
40%，因此 TPP 协定内容将会对世界经济格局及全球 IPR 体制产生极大的冲击。 































第一章  TPP 协定对医药行业影响 
    2015 年 11 月 5 日，商务部在其网站上公布了跨太平洋伙伴关系协定（TPP）
全文译本，其中第十八章即关于知识产权的规定再一次证实了世界后 TRIPS 时代的





第一节  TPP 协定签署背景 
一、WTO 多边谈判谈判陷入僵局 









TPP 协定协议共有 30 个章节，覆盖领域广泛的商业及与商业相关的问题，除了对
现有自由贸易协定（FTA）贸易争端的原有处理方式进行调整之外，TPP 协定也呈
现了一些全新的、正在萌发的商业贸易问题和交叉性问题。 
自 1994 年 TRIPS 协定达成以来至今的知识产权规则变革和发展趋势（后 TRIPS
时期）以 TRIPS 协定为基准可分为主要为发达国家主张超 TRIPS 标准的知识产权
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